Wugen, Inc.: Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress

-- WU-CART-007 was well-tolerated in patients with R/R T-ALL/LBL, with low incidence of high-grade CRS and immune-related adverse events -- -- WU-CART-007 demonstrated preliminary evidence of anti-leukemic

Related Keywords

Germany ,Zeiten ,Mecklenburg Vorpommern ,Elsie Yau ,Stefan Klotter ,Jan Davidson Moncada ,Wugen Inc ,Drug Administration ,European Hematology Association ,Stern Investor Relations Inc ,Dose Levels ,Chief Medical Officer ,Dose Expansion Study ,T Cell Acute Lymphoblastic ,Lymphoblastic Lymphoma ,Host Disease ,Objective Response Rate ,Infused Memory Like ,Natural Killer ,Cells Elicit Adaptive Immune Responses ,Acute Myeloid Leukemia ,Orphan Drug ,Fast Track ,Rare Pediatric Disease Designations ,Stern Investor Relations ,Stabile Ertr ,Chart Profi Stefan Klotter ,Blue Chips ,